CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Clinical trial NCT02819583 · UNKNOWN

Trial details

NCT number: NCT02819583
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma B-cell Prolymphocytic Leukemia Diffuse Large Cell Lymphoma

Start date: 2016-10-01
Primary completion: 2018-09-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.